vs
Side-by-side financial comparison of FORWARD AIR CORP (FWRD) and NEUROCRINE BIOSCIENCES INC (NBIX). Click either name above to swap in a different company.
NEUROCRINE BIOSCIENCES INC is the larger business by last-quarter revenue ($814.5M vs $631.2M, roughly 1.3× FORWARD AIR CORP). NEUROCRINE BIOSCIENCES INC runs the higher net margin — 24.3% vs -4.5%, a 28.8% gap on every dollar of revenue. On growth, NEUROCRINE BIOSCIENCES INC posted the faster year-over-year revenue change (42.2% vs -0.3%). Over the past eight quarters, NEUROCRINE BIOSCIENCES INC's revenue compounded faster (17.5% CAGR vs 7.9%).
Forward Air Corp is a leading North American asset-light logistics and transportation provider. It offers core services including expedited less-than-truckload freight delivery, final-mile logistics, intermodal transport, warehousing, and supply chain solutions, serving key sectors such as e-commerce, retail, manufacturing, and automotive across the U.S., Canada, and Mexico.
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
FWRD vs NBIX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $631.2M | $814.5M |
| Net Profit | $-28.3M | $197.9M |
| Gross Margin | — | 98.3% |
| Operating Margin | -0.5% | 23.7% |
| Net Margin | -4.5% | 24.3% |
| Revenue YoY | -0.3% | 42.2% |
| Net Profit YoY | 22.2% | — |
| EPS (diluted) | $-0.90 | $1.91 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | — | $814.5M | ||
| Q4 25 | $631.2M | $805.5M | ||
| Q3 25 | $631.8M | $794.9M | ||
| Q2 25 | $618.8M | $687.5M | ||
| Q1 25 | $613.3M | $572.6M | ||
| Q4 24 | $632.8M | $627.7M | ||
| Q3 24 | $655.9M | $622.1M | ||
| Q2 24 | $643.7M | $590.2M |
| Q2 26 | — | $197.9M | ||
| Q4 25 | $-28.3M | $153.7M | ||
| Q3 25 | $-16.3M | $209.5M | ||
| Q2 25 | $-12.6M | $107.5M | ||
| Q1 25 | $-50.6M | $7.9M | ||
| Q4 24 | $-36.4M | $103.1M | ||
| Q3 24 | $-73.4M | $129.8M | ||
| Q2 24 | $-645.4M | $65.0M |
| Q2 26 | — | 98.3% | ||
| Q4 25 | — | 97.8% | ||
| Q3 25 | — | 98.2% | ||
| Q2 25 | — | 98.4% | ||
| Q1 25 | — | 98.4% | ||
| Q4 24 | — | 98.5% | ||
| Q3 24 | — | 98.7% | ||
| Q2 24 | — | 98.4% |
| Q2 26 | — | 23.7% | ||
| Q4 25 | -0.5% | 26.2% | ||
| Q3 25 | 2.4% | 30.1% | ||
| Q2 25 | 3.2% | 21.2% | ||
| Q1 25 | 0.8% | 4.1% | ||
| Q4 24 | 12.0% | 22.6% | ||
| Q3 24 | 3.5% | 29.5% | ||
| Q2 24 | -170.2% | 24.6% |
| Q2 26 | — | 24.3% | ||
| Q4 25 | -4.5% | 19.1% | ||
| Q3 25 | -2.6% | 26.4% | ||
| Q2 25 | -2.0% | 15.6% | ||
| Q1 25 | -8.3% | 1.4% | ||
| Q4 24 | -5.8% | 16.4% | ||
| Q3 24 | -11.2% | 20.9% | ||
| Q2 24 | -100.3% | 11.0% |
| Q2 26 | — | $1.91 | ||
| Q4 25 | $-0.90 | $1.49 | ||
| Q3 25 | $-0.52 | $2.04 | ||
| Q2 25 | $-0.41 | $1.06 | ||
| Q1 25 | $-1.68 | $0.08 | ||
| Q4 24 | $-1.69 | $1.00 | ||
| Q3 24 | $-2.66 | $1.24 | ||
| Q2 24 | $-23.47 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $106.0M | — |
| Total DebtLower is stronger | $1.7B | — |
| Stockholders' EquityBook value | $113.3M | $3.4B |
| Total Assets | $2.7B | $4.9B |
| Debt / EquityLower = less leverage | 14.89× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | — | — | ||
| Q4 25 | $106.0M | $713.0M | ||
| Q3 25 | $140.4M | $340.2M | ||
| Q2 25 | $95.1M | $264.0M | ||
| Q1 25 | $116.3M | $194.1M | ||
| Q4 24 | $104.9M | $233.0M | ||
| Q3 24 | $136.6M | $349.1M | ||
| Q2 24 | $84.9M | $139.7M |
| Q2 26 | — | — | ||
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q2 26 | — | $3.4B | ||
| Q4 25 | $113.3M | $3.3B | ||
| Q3 25 | $139.8M | $3.0B | ||
| Q2 25 | $151.8M | $2.7B | ||
| Q1 25 | $154.6M | $2.5B | ||
| Q4 24 | $201.7M | $2.6B | ||
| Q3 24 | $226.1M | $2.7B | ||
| Q2 24 | $283.8M | $2.5B |
| Q2 26 | — | $4.9B | ||
| Q4 25 | $2.7B | $4.6B | ||
| Q3 25 | $2.8B | $4.3B | ||
| Q2 25 | $2.8B | $3.9B | ||
| Q1 25 | $2.8B | $3.7B | ||
| Q4 24 | $2.8B | $3.7B | ||
| Q3 24 | $3.1B | $3.5B | ||
| Q2 24 | $3.1B | $3.3B |
| Q2 26 | — | — | ||
| Q4 25 | 14.89× | — | ||
| Q3 25 | 12.05× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FWRD
| Omni Logistics Segment | $359.8M | 57% |
| Network | $183.9M | 29% |
| Intermodal Segment | $50.2M | 8% |
| Truckload | $41.6M | 7% |
NBIX
| INGREZZA Net Product Sales | $656.9M | 81% |
| CRENESSITY Net Product Sales | $153.3M | 19% |
| Other Revenues | $4.3M | 1% |
